Search the Newsreel

Adagio Medical Holdings, Inc Revenue Breakdown – NASDAQ:ADGM

The article provides a revenue breakdown for Adagio Medical Holdings, Inc (NASDAQ: ADGM) based on data from TradingView. It offers an overview of the company's financials, including statements, statistics, dividends, earnings, and segment performance. The content is primarily a data placeholder and navigational information …

Adagio Medical Holdings Inc|Price:0.482|Chg%:-0.008

Adagio Medical Holdings Inc (ADGM) has strong fundamentals and high growth potential, despite a recent weak stock market performance. Its valuation is considered fairly priced, with institutional ownership being very high. Analysts have rated it as a Buy, with a target price suggesting a …

Adagio Medical Holdings Inc (ADGM) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of Adagio Medical Holdings Inc's (ADGM) financial health, ranking it 143 out of 200 in the Healthcare Equipment & Supplies industry with a current financial score of 6.66. While its financial status is robust, the operating efficiency is low. …

TradingKey

This article provides a detailed quarterly income statement for Adagio Medical Holdings Inc (ADGM) from FY2021Q4 to FY2026Q1, including key financial metrics like total revenue, operating expenses, net income, and basic/diluted earnings per share. It also includes FAQs explaining how to interpret income statements …

ADAG Q2 2025 Earnings: EPS Misses Estimates as Stock Declines - Share Dilution Risk

Adagio Medical Holdings Inc (ADGM) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article assesses the risk profile of Adagio Medical Holdings Inc (ADGM), noting its current risk score of 1.46, placing it 182nd out of 200 in the Healthcare Equipment & Supplies industry. The company's beta of -0.18 indicates it tends to underperform in bull …

Adagio Medical Holdings, Inc. Interest Coverage (ADGM)

This article provides an analysis of Adagio Medical Holdings, Inc.'s interest coverage ratio. The company's interest coverage was -7.5x in FY2025 and -6.5x on a trailing-twelve-month basis as of Q1 FY26, indicating that its operating income does not cover its interest expenses. The data …

Adagene (ADAG) Morgan Stanley 22nd Annual Global Healthcare Conference Summary

This article summarizes Adagene's presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference, held on January 22, 2026. The company discussed its scientific strategy, focusing on novel epitope targeting and SAFEbody masking technology to enhance antibody-based cancer immunotherapies, particularly for CTLA-4. Key highlights …

Adagene (ADAG) Leerink Global Healthcare Conference 2026 Summary

This article summarizes Adagene's presentation at the Leerink Global Healthcare Conference 2026, highlighting the progress of its lead program, ADG126 (Muza). The drug, a next-generation masked CTLA-4 antagonist, has shown promising efficacy and a favorable safety profile in treating late-line MSS CRC and is …

Adagene (ADAG) Oppenheimer 36th Annual Healthcare Life Sciences Conference summary

This article summarizes Adagene's presentation at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, focusing on the clinical progress of its lead asset, ADG126, a masked anti-CTLA-4 antibody. Key highlights include promising efficacy and safety data, especially in late-line MSS-CRC without liver metastases, and …

Adagene (ADAG) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Adagene (ADAG) presented a summary of its pipeline and clinical data at the H.C. Wainwright 26th Annual Global Investment Conference 2024. The presentation highlighted their lead candidate ADG126, a masked anti-CTLA-4, currently in Phase 2 trials for MSS CRC, demonstrating a wide therapeutic window …

Guggenheim reiterates Adagene stock Buy rating on competitor shift

Guggenheim maintained a Buy rating and $10.00 price target on Adagene Inc. (NASDAQ:ADAG) following a competitor's strategic shift in colorectal cancer treatment. The competitor's discontinuation of a Phase 3 study for late-line metastatic colorectal cancer positions Adagene's muzastotug as the most clinically advanced option …